Abivax SA (ABVX)
Nasdaq · American depositary receipt
As of Oct 21, 2:18 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow ABVX in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on ABVX and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
ABVX at a glance
Key statistics
$8.08B
Market capitalization
- Previous close
- $92.59
- Open
- $93.92
- Day range
- $93.33 – $96.25
- Volume
- 629.4K
- Average volume (30 sessions)
- 1.39M
- Shares outstanding
- 87.27M
- Beta (1 year, vs SPY)
- 1.04
Where the price sits in its year
52-week range
30% of the range
- Below the 52-week high
- -37.1%
- Above the 52-week low
- +34.2%
Completed sessions through Oct 20, 2026
Technical snapshot
Below its 50-day and 200-day averages
- 20-day average
- $91.42+1.3%
- 50-day average
- $105.34-12.1%
- 200-day average
- $115.35-19.7%
Between the conventional 30 and 70 bands.
+7.4%
1 week
-10.5%
1 month
-28.6%
3 months
-31.3%
Year to date
-0.2%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with ABVX
ABVX on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on ABVX.
See the plans →
Every planScreen names like ABVX
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on ABVX
Put ABVX on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on ABVX
See whether there is an open premium alert on ABVX, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
ABVX headlines
- Abivax announces trading resumption of its ordinary shares on Euronext Paris
GlobeNewswire Inc. · Jul 1, 2026
- Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris
GlobeNewswire Inc. · Jul 1, 2026
- Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
GlobeNewswire Inc. · Jul 1, 2026
- What's Going On With Abivax Stock On Thursday?
Benzinga · Jun 4, 2026
- Abivax CEO Downplays Sale Talk, Eyes Capital Raise As Key Trial Data Readout Nears
Benzinga · Mar 24, 2026
- Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline
Benzinga · Mar 12, 2026
- Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
GlobeNewswire Inc. · Feb 21, 2026
- What's Happening With French Biotech Abivax Stock On Wednesday?
Benzinga · Dec 10, 2025
SEC Form 4, most recent first
Insider filings
No insider transactions reported for ABVX recently. ETFs and many foreign issuers do not file Form 4.
About Abivax SA
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
- Exchange
- Nasdaq
- Security
- American depositary receipt
- Employees
- 69
- Listed since
- Oct 20, 2023
- Website
- abivax.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.